Filing Details

Accession Number:
0000905718-22-000521
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-31 17:29:28
Reporting Period:
2022-03-29
Accepted Time:
2022-03-31 17:29:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484565 Soleno Therapeutics Inc SLNO Electromedical & Electrotherapeutic Apparatus (3845) 770523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1762451 Andrew Sinclair 203 Redwood Shores Pkwy
Ste 500
Redwood City CA 94065
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-29 7,720,000 $0.00 18,022,602 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant (right to buy) Acquisiton 2022-03-29 7,720,000 $0.00 7,720,000 $0.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,720,000 2022-03-29 2027-03-29 No 4 P Indirect
Footnotes
  1. The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
  2. An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
  3. Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25.